Çѱ¹Ç÷ÀüÁöÇ÷ÇÐȸ Á¦41Â÷ KSTH Ãß°èÇмú´ëȸ : 2022-09-30±³À°ÀÏÀÚ : 2022-09-30
±³À°Àå¼Ò : ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ 5F ÄÁÆÛ·±½º·ë
±³À°ÁÖÁ¦ :
Á¦41Â÷ KSTH Ãß°èÇмú´ëȸÁÖÃÖ±â°ü : Çѱ¹Ç÷ÀüÁöÇ÷ÇÐȸ
´ã´çÀÚ : ±èÁø¾Æ
¿¬¶ôó : 02-790-2426
À̸ÞÀÏ :
ksth@thrombo.or.kr ±³À°Á¾·ù : ³»°ú, ¿Ü°ú, ¼Ò¾Æû¼Ò³â°ú, Á¤Çü¿Ü°ú, ½Å°æ¿Ü°ú, ÈäºÎ¿Ü°ú, À̺ñÀÎÈÄ°ú, ¿µ»óÀÇÇаú, ¹æ»ç¼±Á¾¾çÇаú, ¸¶ÃëÅëÁõÀÇÇаú, ½Å°æ°ú, ÀçÈ°ÀÇÇаú, °áÇÙ°ú, Áø´Ü°Ë»çÀÇÇаú, ÀÀ±ÞÀÇÇаúÀÇ»çÇÐ, ¿¹¹æÀÇÇÐ, »ý¸®ÇÐ, ºÐÀÚ»ý¹°ÇÐ, ¹Ì»ý¹°ÇÐ, ÀÇ·á»çȸÇÐ, ÀÇ·áÀ±¸®ÇÐ, ÀÇ·áÄ¿¹Â´ÏÄÉÀ̼Ç, ÀÇÇб³À°, ÀÇ·áÁ¤Ã¥, ÀÇ·á¹ý, ÀÇ·á°æ¿µ, ±âŸ
Âü¼®¿¹»óÀοø : 150¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
ºÎ»ê±¤¿ª½Ã±³À°½Ã°£ : 11 ½Ã°£ 0ºÐ
¼¼ºÎ¼ö°·á : 30,000¿ø
ºñ°í ±âŸ:10,000¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±âŸ 09-30 ÄÁÆÛ·±½º·ëA 10:20~10:30 °³È¸»ç ()
±³À°½Ã°£ 09-30 ÄÁÆÛ·±½º·ëA 10:30~11:00 Thrombocytopenia in pregnancy : diagnosis and approach to management Á¤Çظ²(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 09-30 ÄÁÆÛ·±½º·ëB 10:30~11:00 Is anticoagulation needed for atrial arrhythmias except for atrial fibrillation? ÇÑ»óÁø(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 09-30 ÄÁÆÛ·±½º·ëA 11:00~11:30 Identifying and Treating of refractory ITP ½Åµ¿¿±(¼¿ïÀÇ´ë)
±³À°½Ã°£ 09-30 ÄÁÆÛ·±½º·ëB 11:00~11:30 Management of LV thrombus in various LV dysfunction tings À§Áø(°¡ÃµÀÇ´ë)
±³À°½Ã°£ 09-30 ÄÁÆÛ·±½º·ëA 11:30~12:00 Vaccine-inducedthrombocytopenia ÃÖÀºÁö(¿ï»êÀÇ´ë)
±³À°½Ã°£ 09-30 ÄÁÆÛ·±½º·ëB 11:30~12:00 Hemostatic strategies for bleeding after antithrombotics and procedures ÀÌÀç±æ(¿¬¼¼ÀÇ´ë)
Åä·Ð 09-30 ÄÁÆÛ·±½º·ëA 12:00~12:30 Panel discussion ¹æ¼ö¹Ì(¼¿ïÀÇ´ë)
Åä·Ð 09-30 ÄÁÆÛ·±½º·ëB 12:00~12:30 Panel discussion ¹ÎÇʱâ(¿¬¼¼ÀÇ´ë)
½Ä»ç 09-30 ÄÁÆÛ·±½º·ëC 12:30~13:30 Lunch ()
±³À°½Ã°£ 09-30 ÄÁÆÛ·±½º·ëA 13:30~14:00 Recent Update of Pulmonary embolism: 2021 ACCP VTE Partial Update ±èÀÌÇü(°æÈñÀÇ´ë)
±³À°½Ã°£ 09-30 ÄÁÆÛ·±½º·ëB 13:30~14:00 Pharmacogenetics of antiplatelet agents ¹Ú»óÇõ(¿ï»êÀÇ´ë)
±³À°½Ã°£ 09-30 ÄÁÆÛ·±½º·ëA 14:00~14:30 When & How to apply the ECMO in patients with massive embolism Á¶¿µÀç(¼¿ïÀÇ´ë)
±³À°½Ã°£ 09-30 ÄÁÆÛ·±½º·ëB 14:00~14:30 Clopidogrel resistence test and management in neurointervention ¿ÀÀç»ó(¼øûÇâÀÇ´ë)
±³À°½Ã°£ 09-30 ÄÁÆÛ·±½º·ëA 14:30~15:00 Pulmonary embolism Alert System ȲÇå±Ô(¼øõÇâÀÇ´ë)
±³À°½Ã°£ 09-30 ÄÁÆÛ·±½º·ëB 14:30~15:00 Platelet function in myeloproliferative neoplasms ¾È¾Æ¸®(°¡Å縯ÀÇ´ë)
ÈÞ½Ä 09-30 15:00~15:30 Coffee break ()
±³À°½Ã°£ 09-30 ÄÁÆÛ·±½º·ëA 15:30~16:30 Oral Presentation-Research and Practice in Thrombosis and Haemostasis ±è³²±Ù(Â÷ÀÇ°úÇдë)
±³À°½Ã°£ 09-30 ÄÁÆÛ·±½º·ëA 16:30~17:00 How to approach clinical bleedings and Bruises? – Bleeding score assessment ¾çÀ¯Áø(ºÎ»êÀÇ´ë)
±³À°½Ã°£ 09-30 ÄÁÆÛ·±½º·ëB 16:30~17:00 How do we know about that COVID-19 vaccination can be associated with ASCVD Events or not? ³ª»óÈÆ(¼¿ïÀÇ´ë)
±³À°½Ã°£ 09-30 ÄÁÆÛ·±½º·ëA 17:00~17:30 Genetic screening & testing in coagulation disorder ±è³²Èñ(µ¿¾ÆÀÇ´ë)
±³À°½Ã°£ 09-30 ÄÁÆÛ·±½º·ëB 17:00~17:30 KSTH experience of managing Central Lab of anti-PF4 test for COVID-19 vaccine related TTS Diagnosis À强¼ö(¿ï»êÀÇ´ë)
±³À°½Ã°£ 09-30 ÄÁÆÛ·±½º·ëA 17:30~18:00 Updates of inhibitor managements in Hemophilia ÀÌÀçÈñ(ÃæºÏÀÇ´ë)
±³À°½Ã°£ 09-30 ÄÁÆÛ·±½º·ëB 17:30~18:00 COVID-19 mRNA Vaccine related Myo-Pericarditis Korean Experiences ±è°èÈÆ(Àü³²ÀÇ´ë)
±âŸ 09-30 ÄÁÆÛ·±½º·ëA 18:00~18:20 ¿ì¼ö¿¬Á¦»ó ¹ßÇ¥ ¹× ½Ã»ó ()